Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-2.25%15.211.8%$131.96m
VRXValeant Pharmaceuticals International, Inc.
-3.46%21.3414.1%$125.57m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.28%145.466.2%$78.47m
PRGOPerrigo Co. Plc
-2.91%46.386.8%$67.08m
SAGESAGE Therapeutics, Inc.
0.11%169.308.6%$65.12m
JAZZJazz Pharmaceuticals Plc
-1.39%129.002.3%$52.46m
HZNPHorizon Pharma plc
-1.77%27.196.7%$42.82m
PTLAPortola Pharmaceuticals, Inc.
-3.51%27.807.5%$41.62m
UTHRUnited Therapeutics Corporation
-2.58%80.7114.3%$39.76m
MDCOMedicines Company
-2.12%35.0320.3%$37.35m
ICLRICON Plc
-1.86%153.414.1%$35.69m
CTLTCatalent Inc
-3.86%53.112.4%$35.12m
ICPTIntercept Pharmaceuticals, Inc.
-3.30%60.9017.2%$33.13m
ZGNXZogenix, Inc.
-2.82%50.019.8%$22.94m
AERIAerie Pharmaceuticals, Inc.
-2.30%23.426.8%$22.84m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.